Company / Cash & Equivalents
Apogee Therapeutics, Inc. Cash & Equivalents History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$141.8M
FY2024
5-year range
$118.3M / $151.9M
FY2022-FY2024
Trend
+19.8%
vs FY2023
Sector context
#117 of 207
Health Care
What the data says
At $142M, Apogee Therapeutics, Inc.'s cash & equivalents ranks #117 of 207 in the Health Care sector. Declined from $152M to $142M over the past 2 years.
Based on SEC 10-K filings.
$142M in FY2024.
Declined from $152M to $142M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#117 of 207 in Health CareTop 57% of 207This company $141.8M Sector average $669.5M
▼
-78.8% below sector average
Key checks
Key Insights
- In FY2024, cash & equivalents increased 19.8% year-over-year.
- Ranks #117 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $141.8M | +19.8% |
| FY2023 | $118.3M | -22.1% |
| FY2022 | $151.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026